Neuromyelitis Optica Spectrum Disorder Market Set for Strong Growth Through 2036 | DelveInsight

The neuromyelitis optica spectrum disorder (NMOSD) market across the 7MM is projected to witness steady growth during the forecast period (2026-2036). This expansion is primarily driven by the rising prevalence of NMOSD, increasing awareness, advancements in diagnostic methodologies, and the anticipated launch of innovative therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), among others, according to DelveInsight.

The recently released NMOSD Market Insights report provides a detailed evaluation of current treatment patterns, emerging NMOSD therapies, individual drug market shares, and both historical and projected market size from 2022 to 2036. The analysis spans key markets, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Neuromyelitis Optica Spectrum Disorder Market Overview
• The NMOSD treatment market across major regions is anticipated to demonstrate consistent growth through 2036.
• The United States held the dominant share of the NMOSD treatment market in 2025 compared to other regions such as the EU4, the UK, and Japan.
• Prevalence rates were higher among females (9.48 per 100,000) than males (3.52 per 100,000), reflecting a female-to-male ratio of nearly 3.5:1.
• Key players including Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, and others are actively developing novel therapies expected to enter the market in the coming years.
• Prominent pipeline candidates include BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), and additional emerging therapies.

Explore current and future NMOSD market size projections here: https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Growth Drivers of the NMOSD Market
Advancements in Diagnostics
Enhanced diagnostic techniques, particularly biomarker-based assays such as AQP4-IgG and MOG-IgG testing, have significantly improved diagnostic precision and reduced delays in identifying NMOSD.

Expansion of Targeted Treatments
The introduction of advanced biologics, including monoclonal antibodies and complement inhibitors targeting immune pathways, has revolutionized treatment strategies and boosted market adoption.

Emerging Therapy Launches
The NMOSD market is expected to undergo notable transformation with the introduction of therapies such as BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), and others.

According to Ramandeep Singh, Senior Consultant at DelveInsight, NMOSD treatment currently involves a multidisciplinary approach focused on symptom control and improving patient quality of life. Although a definitive cure remains unavailable, immunosuppressive therapies play a central role, and recently approved treatments are paving the way for future innovation.

NMOSD Epidemiology Insights
The epidemiology segment provides insights into historical and projected patient populations across major markets.
• Diagnosed prevalence is estimated at approximately 1.5 cases per 100,000 individuals.
• Around 70-80% of patients test positive for anti-AQP4 antibodies.

The report includes segmentation by:
• Total prevalent cases
• Diagnosed cases
• Gender-specific prevalence
• Treated patient population

Download the full report to explore future NMOSD epidemiology insights: https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

NMOSD Market Analysis
Current treatment approaches effectively manage symptoms but do not offer a permanent cure. Acute episodes are generally treated with high-dose intravenous corticosteroids like methylprednisolone.

Long-term management commonly involves therapies such as corticosteroids, azathioprine, mycophenolate mofetil, and rituximab. These are often used in combination, particularly with low-dose steroids. In cases where patients do not respond adequately to corticosteroids, plasma exchange serves as an alternative treatment option.

In July 2025, NHS England implemented a national policy supporting the use of ACTEMRA (tocilizumab) for patients who are intolerant or unresponsive to previous therapies. The treatment is administered through specialized neurology centers.

Although tocilizumab had earlier received approval from MHRA for other inflammatory conditions, this policy marked its specific adoption for NMOSD in the UK.

In the United States, therapies approved by the FDA for NMOSD include ENSPRYNG, ULTOMIRIS, and others.
Meanwhile, pipeline candidates such as BAT4406F, Telitacicept, and Divozilimab continue to drive innovation within the NMOSD treatment landscape.

NMOSD Competitive Landscape
Several investigational therapies are under development for NMOSD, including BAT4406F, Telitacicept (RC18), and Divozilimab (BCD-132).

BAT4406F by Bio-Thera Solutions is a Phase II glyco-engineered monoclonal antibody being studied in China. It is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) and functions as an anti-CD20 antibody that promotes B-cell depletion.

Telitacicept (RC18), developed by RemeGen and Vor Bio, is a fusion protein targeting autoimmune disorders. It works by inhibiting BLyS and APRIL, two molecules essential for B-cell maturation.

Divozilimab (BCD-132), developed by Biocad, is another monoclonal antibody targeting CD20 proteins on B cells. By binding to CD20, it reduces B-cell activity and helps control autoimmune responses. Its safety and efficacy are currently being assessed in clinical trials.

The anticipated approval and commercialization of these therapies are expected to significantly reshape the NMOSD market, introducing new standards of care and unlocking opportunities for medical advancement and economic growth.

Learn more about upcoming NMOSD therapies: Neuromyelitis Optica Spectrum Disorder Drugs - https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

What is Neuromyelitis Optica Spectrum Disorder?
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease in which the immune system attacks the central nervous system, particularly the optic nerves and spinal cord.
This condition can lead to optic neuritis, causing vision impairment and eye pain, as well as transverse myelitis, resulting in muscle weakness, sensory disturbances, and bladder or bowel dysfunction.
NMOSD is commonly associated with antibodies against aquaporin-4 (AQP4), which helps differentiate it from similar conditions like multiple sclerosis. Due to the severity of attacks and potential for long-term disability, early diagnosis and continuous treatment are essential.

Download the full report to explore future NMOSD trends: Neuromyelitis Optica Spectrum Disorder Market Analysis - https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Report Coverage and Scope
• Study Period: 2022-2036
• Geographic Coverage: United States, EU4 (Germany, France, Italy, Spain), United Kingdom, Japan
• Key Companies: Major companies operating in the NMOSD space include Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, Genentech, Chugai Pharmaceuticals, AstraZeneca, Alexion, and others.
• Key Therapies: Notable therapies include BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), ENSPRYNG, ULTOMIRIS, SOLIRIS, and others.

Report Scope Highlights
• Evaluation of existing and emerging therapies
• Market dynamics and forecast assumptions
• Competitive intelligence (SWOT, entry strategies)
• Unmet needs and expert insights
• Market access and reimbursement analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.